No Data
No Data
No Data
Leisure Guard sprinted to become the first “North+H” listed company
As an unprofitable pharmaceutical company, Recreation Guard can be described as an “old player” in the capital market. It has been listed on the New Third Board and Beijing Stock Exchange, and has also introduced multiple rounds of financing during this period
Leisure Guards-B, the first share of “North+H”, submitted an IPO prospectus and plans to go public in Hong Kong, co-sponsor by CITIC and CCB
On January 29, 2024, Beijing Health Guard Biotechnology Co., Ltd. Beijing Health Guard Biotechnology Inc. (“Health Guard” for short) submitted a prospectus on the Hong Kong Stock Exchange to be listed in Hong Kong for an IPO.
Hit the first “North+H” stock! After a year, Leisure Guard went to Hong Kong to IPO, and the nine-valent HPV vaccine war is about to begin?
① Today, Leisure Guard announced that it has submitted a prospectus to the Hong Kong Stock Exchange. If successful, it is expected to become the first “North+H” listed company. ② The company's research pipeline includes 10 recombinant human vaccines and 1 mRNA vaccine, but no vaccine products have been marketed for sale. ③ Industry experts are still optimistic about the HPV vaccine market and believe that trivalent HPV vaccines also have room.
The first “North+H” company was hit. The “first share of the domestically produced nine-valent HPV vaccine” was submitted to the Hong Kong Stock Exchange. It is expected that the nine-valent HPV vaccine will be submitted simultaneously in China and Indone
According to the Hong Kong Stock Exchange's disclosure on January 29, Beijing Kangleguard Biotechnology Co., Ltd. (“Leisure Guard”, Beijing Stock Exchange code: 833575.BJ) submitted a listing application to the main board of the Hong Kong Stock Exchange, with CITIC Securities and CCB International as co-sponsors.
No Data